文献速递银屑病与炎症性皮肤病

真实世界银屑病治疗中富马酸酯诱导的T细胞淋巴细胞减少

Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-02-28

该单中心回顾性观察性亚队列研究纳入371例银屑病患者,在启动富马酸酯(Fumaderm®)治疗前及治疗期间(平均2.9年)监测白细胞和淋巴细胞亚群计数。富马酸酯显著降低CD4+ T、CD8+ T、CD19+ B和CD56+ NK细胞数量,CD8+ T细胞平均降幅最高,治疗2年后达55.7%。T细胞淋巴细胞减少风险随启动治疗时年龄增长而显著增加,甲氨蝶呤联合叶酸补充时显著降低。

要点

  • 富马酸酯显著降低CD4+ T、CD8+ T、CD19+ B和CD56+ NK细胞数量,CD8+ T细胞降幅最大。
  • 启动治疗时年龄越大,T细胞淋巴细胞减少风险显著增加;甲氨蝶呤联合叶酸补充时风险显著降低。
  • 作者建议定期监测CD4+和CD8+ T细胞计数以优化药物警戒,尤其在中老年患者。

核心结论

  • 监测特定T细胞亚群而非仅绝对淋巴细胞计数可能对富马酸酯治疗安全性和有效性提供更有意义的见解。
  • 作者建议通过定期额外监测CD4+和CD8+ T细胞计数来优化药物警戒,尤其是中老年患者。
  • 需要进一步前瞻性研究以建立循证建议,指导皮肤科医生管理使用富马酸酯且出现低绝对T细胞计数的银屑病患者。

研究设计与样本

  • 单中心回顾性观察性亚队列研究,纳入371例银屑病患者(平均年龄47.8岁,63.3%为男性),在启动富马酸酯治疗前获取白细胞和淋巴细胞亚群计数,治疗期间监测(平均治疗时长2.9年)。
  • 采用多参数流式细胞术进行免疫表型分析。

主要发现

  • 富马酸酯显著降低CD4+ T、CD8+ T、CD19+ B和CD56+ NK细胞数量。
  • 在淋巴细胞亚群中,CD8+ T细胞相对基线的平均降低百分比始终最高,治疗2年后达峰值55.7%。
  • T细胞淋巴细胞减少风险随启动富马酸酯治疗时银屑病患者年龄增长而显著增加。
  • 甲氨蝶呤联合叶酸(维生素B9)补充治疗时T细胞淋巴细胞减少风险显著降低。
  • 有支持性证据提示T细胞淋巴细胞减少增强富马酸酯治疗的疗效。

临床怎么用

  • 作者建议通过定期额外监测CD4+和CD8+ T细胞计数来优化药物警戒,尤其是中老年患者。
  • 作者认为需要进一步前瞻性研究以建立循证建议,指导皮肤科医生管理使用富马酸酯且出现低绝对T细胞计数的银屑病患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fumaric acid esters (FAEs) are used to treat psoriasis and are known to cause lymphopenia in roughly 60% of the patients. Much remains to be elucidated about the biological effects of FAEs on lymphocytes. OBJECTIVE: To evaluate the influence of long-term FAE (Fumaderm® ) treatment on peripheral blood CD4+ and CD8+ T cells, CD19+ B cells and CD56+ natural killer (NK) cells in psoriasis. METHODS: In this single-centre retrospective observational subcohort study, we obtained leucocyte and lymphocyte subset counts before initiating FAE therapy in 371 psoriasis patients (mean age, 47.8 years; 63.3% males) and monitored them during treatment (mean treatment duration, 2.9 years). Multiparametric flow cytometry was used for immunophenotyping. RESULTS: FAEs significantly reduced the numbers of CD4+ T, CD8+ T, CD19+ B and CD56+ NK cells. Among lymphocyte subsets, the mean percentage reduction from baseline was always highest for CD8+ T cells, with a peak of 55.7% after 2 years of therapy. The risk of T-cell lymphopenia increased significantly with the age of the psoriasis patients at the time that FAE therapy was initiated. It was significantly decreased for the combination therapy with methotrexate and folic acid (vitamin B9) supplementation. Supporting evidence was found suggesting that T-cell lymphopenia enhances the effectiveness of FAE therapy. CONCLUSIONS: Monitoring distinct T-cell subsets rather than just absolute lymphocyte counts may provide more meaningful insights into both the FAE treatment safety and efficacy. We therefore suggest optimizing pharmacovigilance by additionally monitoring CD4+ and CD8+ T-cell counts at regular intervals, especially in patients of middle to older age. Thus, further prospective studies are needed to establish evidence-based recommendations to guide dermatologists in the management of psoriasis patients who are taking FAEs and who develop low absolute T-cell counts.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Dickel H, Bruckner T, Höxtermann S, et al. Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019. PMID: 30680823. doi:10.1111/jdv.15448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。